Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
MARIETTA, Ga. - MiMedx Group, Inc. (NASDAQ:MDXG), a healthcare company with an impressive 81% gross margin and rated "GREAT" by InvestingPro’s Financial Health Score, announced Monday the introduction of EPIXPRESS, a new fenestrated placental allograft product designed for treating acute and chronic wounds.
The lyophilized human placental-based allograft includes amnion, intermediate, and chorion layers, and features fenestrations to facilitate fluid movement through the tissue. According to the company’s press release, EPIXPRESS is intended to serve as a protective barrier for hard-to-heal wounds. The product launch comes as MiMedx maintains a strong financial position with a current ratio of 4.39, indicating robust operational capability.
Joseph H. Capper, MiMedx Chief Executive Officer, stated that the product builds upon the company’s existing EPIEFFECT offering by incorporating fenestrations to allow for fluid movement through the tissue.
The product is designed to treat various wound types including diabetic foot ulcers and venous leg ulcers. Its structure makes it suitable for deep or tunneling wounds, and the company notes it can be secured with sutures when necessary.
EPIXPRESS joins MiMedx’s portfolio of PURION-processed placental allografts, which includes EPIFIX, EPICORD, EPIEFFECT, CELERA and EMERGE. Like these other products, EPIXPRESS is listed on the Medicare Part B Average Sales Price File.
The company describes the product as containing over 300 regulatory proteins and providing a biocompatible human Extracellular Matrix.
MiMedx, which has been operating in the wound care sector for more than a decade, focuses on products for wound care, burn, and surgical applications. With annual revenue of $364 million and positive earnings per share of $0.21, the company has demonstrated solid market performance. For deeper insights into MiMedx’s financial health and growth potential, including additional ProTips and comprehensive analysis, visit InvestingPro.
In other recent news, MiMedx Group Inc reported impressive financial results for the second quarter of 2025. The company posted earnings per share of $0.10, which was double the forecasted $0.05. Additionally, MiMedx’s revenue reached $98.61 million, surpassing the expected $90.62 million. These strong financial results have led Cantor Fitzgerald to raise its price target for MiMedx to $12.00 from $11.00, while maintaining an Overweight rating. The revenue beat and increased 2025 revenue guidance were key factors in this decision. Cantor Fitzgerald’s estimate of $91.4 million was also exceeded by MiMedx’s reported revenue. These developments reflect positively on the company’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.